MetaCap

Medicinova (MNOV) vs Polaryx Therapeutics (PLYX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Medicinova is the larger company by market cap ($67.1 million vs $66.3 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

MNOV-21.08%PLYX-96.20%
+118%+6%-106%
Feb 2, 20261 yearNov 20, 2026
MNOV-18.13%PLYX-85.07%
+117%+11%-95%
Feb 2, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

MNOV versus PLYX key metrics
MetricMNOVPLYX
Share price$1.31$1.33
Market cap$67.11M$66.30M
1-day change+3.15%-11.92%
YTD return0.00%—
1-year return-8.39%—
5-year return-59.32%—
EPS (TTM)$-0.21$-0.18
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$409.66K—
Net income (latest FY)$-12.00M$-8.98M
Operating margin-3242.47%—
Net margin-2928.78%—
52-week high$3.90$48.91
52-week low$1.22$1.30
Distance from 52-week high-66.41%-97.28%
Analyst consensusstrong_buynone
Avg. price target upside+529.77%+463.91%
Average volume334.96K36.42K
Shares outstanding51.23M49.85M
Employees62
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Medicinova

MNOV stock →

MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It develops MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent in Phase 2 clinical trial for treating neurological and other disorders, such as progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, and glioblastoma, as well as prevention of acute respiratory distress syndrome.

Health Care · Biotechnology: Pharmaceutical Preparations · 6 employees

About Polaryx Therapeutics

PLYX stock →

Polaryx Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of disease-modifying therapies for rare and pediatric lysosomal storage disorders in the United States. Its pipeline includes PLX-100, a preclinical stage orally administrable combination therapy; PLX-200, a repurposed oral small molecule for the treatment of LSDs; PLX-300, a preclinical stage orally administrable combination therapy; and PLX-400, a preclinical stage novel gene therapy candidate.

Health Care · Biotechnology: Pharmaceutical Preparations · 2 employees

MNOV vs PLYX FAQ

Which is bigger, Medicinova or Polaryx Therapeutics?

Medicinova (MNOV) is larger, with a market capitalization of $67.11M compared with $66.30M for Polaryx Therapeutics (PLYX).

Are Medicinova and Polaryx Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons